Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.38

-9.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (9887)	12/31/2003 6:11:52 PM
From: Icebrg	Read Replies (3) of 52153

....of the year awards. I saw that Rick on the NBIX board has nominated Gary Lynch for another CEO of the year award. To complement Rick's nomination, I would like to suggest the following for the Dare-devil of the year award. My nomination in this category goes emphatically to Sepracor's Tim Barberich. By coincidence he is fishing in the same waters as Gary Lynch. The reason for my nomination is mainly the company's recent announcement that they have started four phase IIIb studies of ESTORRA enrolling in total 2.300 persons, before they have even seen FDA approve their still outstanding NDA, which incidently has slipped about 3 months past its original best-before PDUFA-date. And to put these figures in some perspective, it should be mentioned that the NDA is only supported by a 2.700 person patient stock. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next